Comparative Studies on the Effects of Zidovudine, Nevirapine, Lamivudine and Bioclean II on Female HIV/AIDS Cases in Nigeria

Definite cure for HIV/AIDS is not yet documented and over 40 million people in the world are believed to be infected with the virus. The present study evaluates the effects of Zidovudine + Lamivudine + Nevirapine (HAART) and Bioclean II on female HIV/AIDS cases in Nigeria. Candidates on HAART (n=5) were recruited from Central Hospital, Stella Obasanjo Hospital and University of Benin Teaching Hospital, Benin City. The Bioclean II group (n=5) were placed on oral 10 ml twice daily Bioclean II for 8 months. Venous blood samples were collected from each individual in the two treatment groups at 0, 90 and 180 days intervals for analysis for viral load, CD4+T cells and sero-status. The body weights of the individuals were taken at the same time intervals. The mean viral load, CD4+T-cells count and body weights for the HAART Group were 299, 587.8 copies/ml – 199, 854.4 copies/ml; 123.2 cells/µl – 461.2 cells/µl and 44.6 kg – 48.6 kg while the Bioclean Group yielded 304161.8 copies/ml – 2785.0 cells/ml; 123.4 cells/µl – 752.6 cells/µl and 45.0 kg – 61.4 kg respectively. Though the sample size is small and therefore may not provide sufficient grounds for generalization without recourse to small sample theorem, the performance of Bioclean II in the three parameters investigated suggests that Bioclean II has a potential as an intervention tool in HIV/AIDS disease in the population investigated.